Handball and water polo had similarly high occurrence of dental trauma as karate, a high-risk martial art sport. Therefore, the classification of sports according to the risk of dental trauma should be reconsidered. It would be beneficial to make wearing a mouthguard mandatory in all high-risk sports, as well as in those with medium-risk for dental injuries.

The aim of this cross-sectional study was to compare the accuracy of the Cameriere European formula (Cameriere), adopted Haavikko method from 1974 (Haavikko), and revisited Demirjian method by Willems (Willems) for age estimation on orthopantomograms (OPGs) of Bosnian-Herzegovian (BH) children age groups 6-13 years. The accuracy was determined as difference between estimated dental age (DA) and chronological age (CA) and the absolute accuracy (absolute difference) was assessed by analyzing OPGs of 591 girls and 498 boys. The Cameriere method overestimated the mean age by 0.09 year for girls and underestimated by -0.02 year for boys. The Haavikko method underestimated the mean age by -0.29 year for girls and -0.09 year for boys. The Willems method overestimated the mean age by 0.24 year in girls and by 0.42 year in boys. The absolute accuracies were 0.53 year for girls and 0.55 year for boys for Cameriere method; for Haavikko method, 0.59 year for girls and 0.62 year for boys; and for Willems method 0.69 year for girls and 0.67 year for boys. In conclusion, Cameriere method is the most accurate for estimating the age of BH children age groups 6-13 years using OPGs, following adopted Haavikko method and Willems method.

IMPORTANCE Although the Canadian Treat-and-Extend Analysis Trial With Ranibizumab in Patients With Neovascular Age-Related Macular Disease (CANTREAT) reported herein and the Treat and Extend study provided data to show noninferiority of treat-and-extend (T&E) at 12 months, to date there are few data on 24-month T&E trials compared with monthly dosing. OBJECTIVE To compare the efficacy of ranibizumab using a T&E regimen to monthly dosing in treatment-naive patients with neovascular age-related macular degeneration (nAMD) after 24 months. DESIGN, SETTING, AND PARTICIPANTS A randomized, open-label, multicenter, noninferiority intention-to-treat trial with a margin of −5 letters in best-corrected visual acuity (BCVA) from baseline to 12 months between groups was conducted at 27 treatment centers in Canada. Participants included 580 patients with treatment-naive choroidal neovascularization secondary to AMD.

No abstract

No abstract